Brief: Celyad Oncology Announces FDA Clearance Of IND Application For CYAD-211
14/07/2020 06:02
July 14 (Reuters) - Celyad Oncology CYAD.BR :
* CELYAD ONCOLOGY ANNOUNCES FDA CLEARANCE OF IND APPLICATION
FOR
CYAD-211, FIRST SHRNA-BASED, NON-GENE EDITED ALLOGENEIC CAR T
THERAPY
* CYAD-211 REPRESENTS COMPANY'S FIRST ALLOGENEIC CAR T
CLINICAL
CANDIDATE USING SHRNA TECHNOLOGY
* PHASE 1 CLINICAL TRIAL EVALUATING OFF--SHELF ANTI-BCMA CAR
T
CANDIDATE CYAD-211 EXPECTED TO BEGIN BY YEAR-END 2020
Source text for Eikon: ID:nBw9l19gZa
Further company coverage: CYAD.BR
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))